Aspire Biopharma聘请了DNA运送专家Mark Jaroszeski博士,以推进其亚语言毒品平台。 Aspire Biopharma hired Dr. Mark Jaroszeski, a DNA delivery expert, to advance its sublingual drug platform.

2025年11月4日宣布,南佛罗里达大学教授、DNA和药物运送技术先锋Mark J. Jaroszeski博士加入了科学团队。 Aspire Biopharma (NASDAQ: ASBP) announced on November 4, 2025, that Dr. Mark J. Jaroszeski, a University of South Florida professor and pioneer in DNA and drug delivery technologies, has joined its scientific team. Jaroszeski博士以其在活体电解和定向药物交付方面的工作著称,他带来了数十年的经验、100多次受他的研究影响的临床试验以及34项美国专利。 Dr. Jaroszeski, known for his work in in vivo electroporation and targeted drug delivery, brings decades of experience, over 100 clinical trials influenced by his research, and 34 U.S. patents. 他将支持Aspire开发一个专利支用小语言发送平台, 直接将药物送到血液中, 可能通过绕过胃肠道, 提高效果及减少副作用。 He will support Aspire’s development of a patent-pending sublingual delivery platform designed to deliver drugs directly into the bloodstream, potentially improving efficacy and reducing side effects by bypassing the gastrointestinal tract. 该技术旨在加强对小型和大型分子、营养学和补充剂的治疗。 The technology aims to enhance treatment for small and large molecules, nutraceuticals, and supplements.